Pediatric Blood & Cancer · 20 Nov 2026
From Data to Duty: An Informatics Blueprint for Pediatric Oncology Trials
Kirk D. Wyatth-index 6, Andrew D. Tran, Suzi Birz, Michael Watkins, Jeremy L. Warner, Heather Wasserstrom, Grace E. Rossi, Elyssa Rubin, Charles A. Phillips, Angela J. Waanders, David H. Noyd, Nicole Wood, Reuven J. Schore, Natasha Alexander, Brian Furner, Wayne H. Liang, Jennifer Wilkes, Yang Yang Ding, Ajay Perumbeti, Tamara P. Miller, Karen Lewing, Gerard Hills, Colin Moore, Ksenya Shliakhtsitsava, Tyler J. Benning, Anna Keller, Emily M. Webb, Hope Humann, Emily Larimer, Harry Hochheiser, Adam P. Yan, Amir Mian, Amanda Haddock, Parker Moss, Molly S. Talman, Lynda M. Villagomez, Subhashini Jagu, Allen R. Chen, Sara M. Dryden, Richard Aplenc, Samuel L. Volchenboumh-index 9
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
ABSTRACT The data generated by cooperative‐group clinical trials have transformed outcomes for children with cancer, yet the infrastructure underlying their collection and use has not kept pace with advances in informatics and data science. Data collection on pediatric oncology trials remains largely manual: Clinical research assistants abstract values from medical records and key them into electronic case report forms, a process that is costly, slow, inconsistent, and error‐prone. Data are often siloed within trial networks for years after a study closes, limiting their value for secondary research, particularly for rare cancers. In this consensus blueprint, an interdisciplinary group of pediatric oncologists, clinical informaticians, data scientists, nurses, clinical research assistants, drug developers, and parent advocates outlines a pragmatic path forward across three components of the data lifecycle: collection, processing, and sharing. We argue that case report forms should be bound to standardized common data elements; that automated data abstraction from electronic health records, including via large language models with human‐in‐the‐loop validation, should replace much of today's manual abstraction; that paper chemotherapy roadmaps should be reconceived as computable artifacts; and that clinical trials data should be deposited in publicly accessible repositories with appropriate governance as soon as practically feasible. We discuss facilitators and barriers within each component, including standards adoption, regulatory complexity, financial sustainability, and workforce capacity. We propose concrete actions for funders, clinical trials networks, professional societies, and industry. The technology to achieve these goals exists today, and widespread adoption requires coordinated leadership, sustainable funding models, and a cultural shift that recognizes data stewardship as an ethical imperative and a duty to the children and families we serve.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Samuel L. Volchenboum has the highest h-index among the authors (9).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (35)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 15 more references
A free account opens the rest of the citing papers and references on every paper’s page.